Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • 5th SSHO in St. Gallen

How do advances in treatment translate to clinical practice?

    • Congress Reports
    • Oncology
    • RX
  • 4 minute read

Several studies in the area of chronic lymphocytic leukemia have attracted attention in recent years, most notably, of course, the CLL11 study, which demonstrated a clear benefit of the combination of chlorambucil plus GA101 in a comorbid population. PD Dr. med. Barbara Eichhorst from the University Hospital of Cologne took a close look at progress in the field of CLL and presented a review of research to date at the 5th SSHO in St. Gallen. She was particularly concerned with the relevance for concrete clinical practice.

(ag) Already in the CLL8 trial presented at the 2012 ASH Congress, FC (fludarabine, cyclophosphamide) plus rituximab showed significantly better overall survival than FC alone at a median observation time of 5.9 years. “In terms of progression-free survival, it was found that the so-called immunoglobulin HV (IGHV) mutation status was a key contributor to the success of the treatment. FCR provided an extremely good outcome within the group with mutated IGHV, with many of the participants still in remission after eight years on this therapy, which is close to a cure. In addition, however, it was equally surprising how strongly those patients with the unmutated form responded to the antibody. They achieved almost the same good results as those on FC and mutated IGHV,” explained PD Barbara Eichhorst, MD, Cologne, at the fifth Swiss Summit on Hemato-Oncology (SSHO) at the Cantonal Hospital St. Gallen. “The CLL10 study [1] investigated patients with untreated, active chronic lymphocytic leukemia (CLL) without del(17p) who had good physical fitness. The CIRS(“Cumulative Illness Rating Scale”) score was ≤ 6, and creatinine clearance was ≥ 70 ml/min. The purpose was to compare FCR with a combination of bendamustine and rituximab (BR) in the first-line setting. Regarding progression-free survival, the primary endpoint, there was a statistically relevant inferiority of BR compared to FCR (p=0.041). Although study participants were not selected for their IGHV mutation status, it presented as an independent prognostic factor for progression-free survival.

In terms of response and minimal residual disease (MRD), FCR also showed significantly better results. However, because more severe side effects such as neutropenia and infections also occurred with this therapy, no safe recommendation could be made at the time of the study regarding either regimen in the population of physically fit CLL patients.”

So how can first-line treatment be improved in these patients? “The answer is not simple. What is certain is that minimal residual disease is crucial for a positive prognosis at the end of therapy. High residual disease means a high risk of early recurrence,” Dr. Eichhorst said.

Comorbid CLL patients

The counterpart to the CLL10 study, which included only patients with a maximum CIRS score of 6 points and normal renal function, is the CLL11 study [2]. She studied a population of comorbid (CIRS >6) patients with creatinine clearance of <70 ml/min. This is consistent with the typical patient seen in clinical practice, as CLL occurs at a median older age where comorbidities are commonplace. Chlorambucil (Clb) was compared with the new CD20 antibody GA101 (obinutuzumab) plus Clb (GClb) and rituximab plus Clb (RClb) in stage 1, and the two antibodies were compared head-to-head (stage 2).

While the stage 1 analysis showed a clear advantage for the combination with antibodies (both rituximab and obinutuzumab), the stage 2 analysis demonstrated a highly significant prolonged progression-free survival and an improved complete remission rate under GClb compared to RClb. “Furthermore, it is particularly significant that MRD negativity (in blood and bone marrow) was achieved ten times more frequently with the new antibody than with RClb. As mentioned, this is crucial for the long-term outcome,” Dr. Eichhorst explained.

The Complement 1 trial [3] has a slightly different study design: it also compares a CD-20 monoclonal antibody, namely ofatumumab, as an adjunct to chlorambucil with chlorambucil alone (phase III). The study population consisted of previously untreated CLL patients who were not eligible for fludarabine-based therapy. With the antibody, improvements were seen in several clinically relevant outcomes, most notably progression-free survival (22.4 vs. 13.1 months, p<0.001).

Better and less toxic?

Recently, a phase III study [4] was published in the New England Journal of Medicine that caused quite a stir. She compared the inhibitor idelalisib (inhibitor of phosphoinositide 3-kinase[PI3K]-delta) in combination with rituximab with placebo plus rituximab in a sample of partially comorbid patients with relapsed CLL. The goal was to find a therapy that had an acceptable side effect profile for this sensitive population. “Indeed, there was a surprisingly large, highly significant difference in median progression-free survival and response, as well as other significant benefits in overall survival (p=0.02) in favor of rituximab plus idelalisib. Severe adverse events were more common with this combination than with rituximab plus placebo, to be sure. Nevertheless, the agent is likely to be approved in the U.S. in the near future, not least because of its surprising results in overall survival. Moreover, the data on ibrutinib are also encouraging, so there are several agents in the pipeline,” Dr. Eichhorst concluded.

Source: 5th Swiss Summit on Hemato-Oncology (SSHO), March 20, 2014, St. Gallen, Switzerland.

Literature:

  1. Eichhorst B, et al: Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). ASH Abstract #526.
  2. Goede V, et al: Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) And Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. ASH Abstract #6.
  3. Hillmen P, et al: Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). ASH Abstract #528.
  4. Furman RR, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014 Mar 13; 370(11): 997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.

InFo Oncology & Hematology 2014; 2(5): 28-29.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Chlorambucil
  • CIRS
  • CLL
  • FCR
  • IGHV
  • leukemia
  • SSHO
Previous Article
  • Pediatric hematology and oncology

Acute childhood leukemias: an update.

  • Education
  • Hematology
  • Oncology
  • Pediatrics
  • RX
View Post
Next Article
  • Chronic wounds

Better sheets, smart beds and innovations from veterinary medicine

  • Congress Reports
  • Dermatology and venereology
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.